Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

BUY
$3.6 - $5.25 $4,456 - $6,499
1,238 Added 2.29%
55,345 $241,000
Q1 2023

May 15, 2023

SELL
$4.3 - $8.27 $41,366 - $79,557
-9,620 Reduced 15.1%
54,107 $240,000
Q4 2022

Feb 14, 2023

BUY
$5.66 - $8.42 $360,694 - $536,581
63,727 New
63,727 $536,000
Q2 2022

Aug 15, 2022

BUY
$2.6 - $6.14 $171,600 - $405,240
66,000 Added 48.53%
202,000 $632,000
Q1 2022

May 13, 2022

BUY
$5.08 - $9.81 $453,136 - $875,052
89,200 Added 190.6%
136,000 $775,000
Q4 2021

Feb 11, 2022

BUY
$8.55 - $111.89 $13,680 - $179,024
1,600 Added 3.54%
46,800 $458,000
Q2 2021

Aug 12, 2021

BUY
$85.37 - $114.1 $845,163 - $1.13 Million
9,900 Added 28.05%
45,200 $3.86 Million
Q1 2021

May 17, 2021

SELL
$109.73 - $153.66 $120,703 - $169,026
-1,100 Reduced 3.02%
35,300 $4.05 Million
Q4 2020

Feb 03, 2021

SELL
$79.58 - $152.45 $206,908 - $396,369
-2,600 Reduced 6.67%
36,400 $5.1 Million
Q3 2020

Nov 16, 2020

SELL
$66.43 - $90.99 $79,716 - $109,188
-1,200 Reduced 2.99%
39,000 $3.18 Million
Q2 2020

Aug 12, 2020

BUY
$44.04 - $80.69 $444,804 - $814,969
10,100 Added 33.55%
40,200 $2.89 Million
Q1 2020

May 06, 2020

BUY
$44.49 - $93.39 $182,409 - $382,899
4,100 Added 15.77%
30,100 $1.34 Million
Q3 2019

Nov 12, 2019

BUY
$31.0 - $89.73 $167,400 - $484,542
5,400 Added 26.21%
26,000 $2.04 Million
Q2 2019

Aug 14, 2019

BUY
$36.0 - $44.73 $349,200 - $433,880
9,700 Added 88.99%
20,600 $893,000
Q1 2019

May 13, 2019

BUY
$33.79 - $51.99 $81,096 - $124,776
2,400 Added 28.24%
10,900 $441,000
Q3 2018

Nov 14, 2018

BUY
$31.25 - $47.64 $265,625 - $404,940
8,500 New
8,500 $382,000

Others Institutions Holding ALLK

About Allakos Inc.


  • Ticker ALLK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 84,726,096
  • Market Cap $24.6M
  • Description
  • Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...
More about ALLK
Track This Portfolio

Track State Of Wisconsin Investment Board Portfolio

Follow State Of Wisconsin Investment Board and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Of Wisconsin Investment Board, based on Form 13F filings with the SEC.

News

Stay updated on State Of Wisconsin Investment Board with notifications on news.